TY - JOUR
AR - DDA-2019-1-102
TI - Evaluation of The In Vitro And In Vivo Inhibitory Effects of Enrofloxacin On the Growth of Babesia Species and Theileria Equi
AU -  Ikuo , Igarashi
AU -  Naoaki , Yokoyama
AU - Akram , Salama
AU - Amer , AbdEl-Aziz
AU - Mahmoud , AbouLaila
AU - Rehab , Mady
AU - Soad , Menshawy
JO - Drug and Drug Abuse
PY - 2019
DA - Thu 25, Jul 2019
SN - 2674-5062
DO - http://dx.doi.org/10.31487/j.DDA.2019.01.02
UR - https://www.sciencerepository.org/evaluation-of-the-In-Vitro-and-in-vivo-inhibitory-effects-of-enrofloxacin-on-the-growth-of-babesia-species-and-theileria-equi_DDA-2019-1-102 
KW - Enrofloxacin, babesia, theileria equi, in vitro, in vivo
AB - Objectives: Enrofloxacin, a fluoroquinolone antibiotic, is an inhibitor of prokaryotic topoisomerase II with
antibacterial and antiparasitic activities. The study aimed to evaluate the inhibitory effect of enrofloxacin
on Babesia species and Theileria equi in vitro and in vivo.
Methods: The inhibitory effects of enrofloxacin were evaluated in vitro cultures using in vitro inhibition
assay of three Babesia species and Theileria equi; furthermore, the in vivo inhibitory effect of enrofloxacin
was evaluated in the mice model of Babesia microti.
Results: The IC50 values of enrofloxacin were 4.9, 4.5, 4, and 3.9 nM for B. bovis, B. bigemina, B. caballi,
and B. equi, respectively. Enrofloxacin at a dose rate of 10 mg/kg resulted in a 92.9 % inhibition of Babesia
microti growth in BALB/c mice. Combination therapy of enrofloxacin at a dose rate of 5 mg/kg with
diminazene aceturate at a dose rate of 12.5 mg/kg resulted in 93.83 % inhibition of Babesia microti growth
in BALB/c mice.
Conclusions: Enrofloxacin might be used for drug therapy in babesiosis